Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Study: Evaluation of the Safety and Efficacy of Brivaracetam in Subjects (≥ 16 to 70 Years Old) Suffering From Localization-related or Generalized Epilepsy.

NCT00504881 is registered in ClinicalTrials.gov with UCB Pharma SA as lead sponsor.

NCT NCT00504881
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00504881 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Study: Evaluation of the Safety and Efficacy of Brivaracetam in Subjects (≥ 16 to 70 Years Old) Suffering From Localization-related or Generalized Epilepsy.
Lead sponsor
UCB Pharma SA
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2007
Completion date
December 31, 2008
Enrollment
480 (actual)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsy